(Q36960755)

English

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

scientific article published on September 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1 reference

Europe PubMed Central

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Lothar H Finke

1

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Kerry Wentworth

2

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Brent Blumenstein

3

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Natalie S Rudolph

4

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Hyam Levitsky

5

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Axel Hoos

6

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

language of work or name

0 references

publication date

1 September 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

25 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

B97-B109

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Active-specific immunotherapy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Association of HLA phenotype with response to active specific immunotherapy of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Vaccine therapy for melanoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Autologous renal cell cancer vaccines using heat shock protein-peptide complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Natural Killer andNK-LikeT-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Ganglioside expression in lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Development of the PANVAC-VF vaccine for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Effect of renal cell carcinomas on the development of type 1 T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

A clinical development paradigm for cancer vaccines and related biologics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Enhancing cancer vaccines with immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Enhancing efficacy of therapeutic vaccinations by combination with other modalities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.067

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.06.067

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36960755&oldid=1514625699"